Distillate hydrofining catalyst and a process for the preparation of the
same
    24.
    发明授权
    Distillate hydrofining catalyst and a process for the preparation of the same 失效
    馏分加氢精制催化剂及其制备方法

    公开(公告)号:US5914290A

    公开(公告)日:1999-06-22

    申请号:US884814

    申请日:1997-06-30

    摘要: The present invention discloses a hydrofining catalyst. The catalyst has the following composition based on the total weight of the entire catalyst composition: 1-5%(wt.) nickel oxide, 12-35% (wt.) tungsten oxide, 1-9% (wt.) fluorine, and the balancing amount of composite alumina. Said composite alumina is composed of one or several kinds of micropore alumina and one or several kinds of macropore alumina, wherein the weight ratio of micropore alumina to macropore alumina is 75:25 to 50:50. The term "micropore alumina" in the context means the alumina in which the volume of the proe of diameter less than 80 angstrom occupies more than 95% of its total pore volume, while the term "macropore alumina" in the contest means the alumina in which the volume of the pore of diameter 60-600 angstrom occupies more than 70% of its total pore volume. The pore distribution mentioned above is determined by BET method of nitrogen adsorption at low temperature. This catalyst is especially suitable for the hydrofining of inferior distillates with high sulfur content and boiling range of 80-550.degree. C.

    摘要翻译: 本发明公开了一种加氢精制催化剂。 催化剂具有以下催化剂组合物总重量的组成:1-5%(重量)氧化镍,12-35%(重量)氧化钨,1-9%(重量)氟,和 复合氧化铝的平衡量。 所述复合氧化铝由一种或几种微孔氧化铝和一种或几种大孔氧化铝组成,其中微孔氧化铝与大孔氧化铝的重量比为75:25至50:50。 在本文中,术语“微孔氧化铝”是指直径小于80埃的原型体积占其总孔体积的95%以上的氧化铝,而比较中的术语“大孔氧化铝”是指氧化铝 其直径为60-600埃的孔的体积占其总孔体积的70%以上。 上述孔分布由低温氮吸附的BET法测定。 该催化剂特别适用于高硫含量和沸程为80-550℃的劣质馏分的加氢精制。

    NONLINEAR SIGNAL PROCESSING METHOD AND APPARATUS FOR PULSED-BASED ULTRA-WIDEBAND SYSTEM
    27.
    发明申请
    NONLINEAR SIGNAL PROCESSING METHOD AND APPARATUS FOR PULSED-BASED ULTRA-WIDEBAND SYSTEM 审中-公开
    基于脉冲超声波系统的非线性信号处理方法及装置

    公开(公告)号:US20130058381A1

    公开(公告)日:2013-03-07

    申请号:US13600681

    申请日:2012-08-31

    IPC分类号: H04B1/707

    CPC分类号: H04B1/71637

    摘要: A method and apparatus are provided for processing a received pulsed-based ultra-wideband (UWB) signal before the signal is demodulated by an energy detection based receiver. A nonlinear signal processing unit contains one or multiple subunits, and each subunit consists of a nonlinear device and a filter. The nonlinear devices can be any devices that can shift signal, noise, and interference spectra in a nonlinear fashion, and include but are not limited to square law devices and Teager-Kaiser operators. By applying the nonlinear signal processing unit on the received UWB signal, a major part of the energy of noise and narrowband interferences is shifted to specific frequency ranges and then removed by the appropriate filter(s) in the nonlinear signal processing unit. Thus, the signal-to-noise-plus-interference ratio (SNIR) of the received UWB signal can be improved.

    摘要翻译: 提供一种方法和装置,用于在由基于能量检测的接收机解调信号之前处理接收的基于脉冲的超宽带(UWB)信号。 非线性信号处理单元包含一个或多个子单元,每个子单元由非线性设备和滤波器组成。 非线性器件可以是可以以非线性方式移动信号,噪声和干扰光谱的任何器件,并且包括但不限于平方律器件和Teager-Kaiser算子。 通过对所接收的UWB信号应用非线性信号处理单元,将噪声和窄带干扰能量的主要部分移动到特定频率范围,然后通过非线性信号处理单元中的适当滤波器去除。 因此,可以提高接收的UWB信号的信噪比加干扰比(SNIR)。

    Chemical Compounds
    28.
    发明申请
    Chemical Compounds 审中-公开
    化学化合物

    公开(公告)号:US20080269291A1

    公开(公告)日:2008-10-30

    申请号:US12093750

    申请日:2006-11-17

    IPC分类号: A61K31/454 C07D401/04

    CPC分类号: C07D401/04

    摘要: The invention is directed to novel indolecarboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): where R1, R2, R3 and X are defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).

    摘要翻译: 本发明涉及新的吲哚甲酰胺衍生物。 具体地,本发明涉及式(I)的化合物:其中R1,R2,R3和X定义如下。 这些化合物可用于治疗与不适当的IKK2(也称为IKKβ)活性相关的疾病,特别是治疗和预防包括炎性和组织修复障碍在内的IKK2机制介导的疾病。 这些疾病包括类风湿性关节炎,哮喘和COPD(慢性阻塞性肺疾病)。